Table 3 Histopathological characteristics of ovarian masses included in the study
Variable | Ovarian masses, number (%) |
|---|---|
 Benign | 132 (48.2) |
 Malignant | 142 (51.8) |
 Total | 274 (100.0) |
Histopathological type of benign masses | Â |
 Serous cystoadenoma/cystoadenofibroma | 48 (36.4) |
 Mucinous cystoadenoma | 9 (6.8) |
 Endometrioma | 12 (9.1) |
 Ovarian fibroma/fibrothecoma | 38 (28.8) |
 Teratoma | 8 (6.1) |
 Pelvic inflammatory disease | 2 (1.5) |
 Peritoneal cyst/pseudocysts | 3 (2.3) |
 Hydrosalpinx | 7 (5.3) |
 Paraovarian cyst / paratubaric cyst | 5 (3.8) |
 Total | 132 (100.0) |
Histopathological type of malignant masses | Â |
 High-grade serous ovarian cancer | 58 (40.9) |
 Low-grade serous ovarian cancer | 6 (4.2) |
 Serous borderline tumour | 12 (8.5) |
 Mucinous borderline tumour gastrointestinal type | 7 (4.9) |
 Mucinous borderline tumour endocervical type | 5 (3.5) |
 Mucinous ovarian cancer | 2 (1.4) |
 Endometrioid ovarian cancer | 4 (2.8) |
 Clear cell ovarian cancer | 4 (2.8) |
 Granulosa cell ovarian tumour | 3 (2.1) |
 Ovarian carcinosarcoma | 5 (3.5) |
 Dysgerminoma | 1 (0.7) |
 Ovarian metastases from other tumour | 22 (15.5) |
 Tubal cancer | 1 (0.7) |
 Yolk sac tumour | 3 (2.1) |
 Immature teratoma | 6 (4.2) |
 Sertoli Leydig tumour | 3 (2.1) |
 Total | 142 (100.0) |
FIGO stage of primitive ovarian cancers | Â |
 IA | 26 (21.7) |
 IB | 2 (1.7) |
 IC1 | 4 (3.3) |
 IC2 | 1 (0.8) |
 IC3 | 6 (5.0) |
 IIA | 3 (2.5) |
 IIB | 6 (5.0) |
 IIIA1 | 6 (5.0) |
 IIIA2 | 1 (0.8) |
 IIIB | 9 (7.5) |
 IIIC | 37 (30.8) |
 IVA | 5 (4.2) |
 IVB | 14 (11.7) |
 Total | 120 (100.0) |